Lusefi®, an oral anti-diabetic for type 2 diabetes mellitus which has just been launched by Taisho Pharmaceutical is expected to provide adequate glycaemic control, which lowers blood glucose and serve as a new alternative prescription.
It is an orally-active second generation sodium-glucose cotransporter 2 (SGLT2) inhibitor that is developed and produced by Taisho Pharmaceutical Japan. Formulated with a unique new mechanism of action that selectively inhibits SGLT2 – this treatment lowers blood glucose levels by inhibiting the reabsorption of glucose in the renal tubule, thus increasing urinary glucose excretion and eventually reducing blood glucose levels. Ideal for type 2 diabetes mellitus patients aged 20 and above.
A clinical study on Lusefi® that was conducted in Japan demonstrated excellent improvement in the blood glucose level for both monotherapy and in combination with six types of of oral antidiabetic drugs. The glucose level was sutained for up to 52 weeks. At the end of the study, it was found that in addition to lowering and maintaining a healthy blood glucose level, the anti glycaemic effect of Lusefi® also helped patients decrease their Body Mass Index (BMI) score. Throughout the study, Lusefi® also demonstrated excellent safety profile.
Lusefi® with its active ingredients of Luseogliflozin Hydrate is available in 2.5mg and 5mg tablets via doctors’ prescription.
Dr Zanariah Hussein, Consultant Endrocrinologist at Hospital Putrajaya and Dr Chan Siew Pheng, Consultant Endrocrinologist at Subang Jaya Medical Centre were also present at the media launch event to discuss the rising prevalence of Type 2 Diabetes in Malaysia as well as the research that has been conducted in the field of diabetes.
